[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020010715A - Sintesis de lixisenatida con taponamiento. - Google Patents

Sintesis de lixisenatida con taponamiento.

Info

Publication number
MX2020010715A
MX2020010715A MX2020010715A MX2020010715A MX2020010715A MX 2020010715 A MX2020010715 A MX 2020010715A MX 2020010715 A MX2020010715 A MX 2020010715A MX 2020010715 A MX2020010715 A MX 2020010715A MX 2020010715 A MX2020010715 A MX 2020010715A
Authority
MX
Mexico
Prior art keywords
coupling
synthesis
amino acid
capping
lixisenatide
Prior art date
Application number
MX2020010715A
Other languages
English (en)
Inventor
Bernd Henkel
Tobias Metzenthin
Manfred Gerken
Wolfgang Fiedler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62002530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020010715(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MX2020010715A publication Critical patent/MX2020010715A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/063—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for alpha-amino functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/062—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for alpha- or omega-carboxy functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/064—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for omega-amino or -guanidino functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C07K1/066—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for omega-amido functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para la síntesis de un polipéptido que comprende una secuencia de aminoácidos predeterminada. El método de acuerdo con la invención comprende ciclos de acoplamiento para acoplar, una unidad estructural de aminoácidos C-terminal protegida en el N-terminal a un grupo amino N-terminal desprotegido de una cadena de aminoácidos, en donde al menos un ciclo de acoplamiento comprende una etapa de acoplamiento (a), una etapa de taponamiento (b), y una etapa de desprotección (c).
MX2020010715A 2018-04-10 2019-04-10 Sintesis de lixisenatida con taponamiento. MX2020010715A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18166551 2018-04-10
PCT/EP2019/059090 WO2019197469A1 (en) 2018-04-10 2019-04-10 Lixisenatide synthesis with capping

Publications (1)

Publication Number Publication Date
MX2020010715A true MX2020010715A (es) 2021-01-08

Family

ID=62002530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010715A MX2020010715A (es) 2018-04-10 2019-04-10 Sintesis de lixisenatida con taponamiento.

Country Status (14)

Country Link
US (1) US11028123B2 (es)
EP (1) EP3774838B1 (es)
JP (1) JP7332620B2 (es)
CN (1) CN112218876B (es)
AU (1) AU2019250362A1 (es)
BR (1) BR112020020647A2 (es)
CA (1) CA3096495A1 (es)
DK (1) DK3774838T3 (es)
ES (1) ES2928207T3 (es)
HU (1) HUE059777T2 (es)
IL (1) IL277836A (es)
MX (1) MX2020010715A (es)
SG (1) SG11202010016QA (es)
WO (1) WO2019197469A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019197469A1 (en) 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Lixisenatide synthesis with capping

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JP3107488B2 (ja) 1993-09-29 2000-11-06 株式会社資生堂 架橋ヒアルロン酸を用いた徐放性製剤及び塞栓剤
JP2001501593A (ja) 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸運動を調節するための方法
PA8442401A1 (es) 1996-12-09 2000-05-24 Guilford Pharm Inc Inhibidores polipropilos de ciclofilina
CA2277112C (en) 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
EP1019077B2 (en) 1997-08-08 2010-12-22 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
DK1032587T4 (da) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonist-forbindelser
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
JP2002521319A (ja) 1998-07-23 2002-07-16 メタファー・インコーポレイテッド ポリヒドロキサメートおよびそのアナログのライブラリー
GB9818730D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1296756B1 (de) * 2000-03-28 2006-09-27 Laser- und Medizin-Technologie GGmbH Berlin Verfahren und vorrichtung zur untersuchung der molekularen wechselwirkungen von löslichen oder suspendierbaren wirkstoffen mit festphasen-gebundenen peptidischen oder peptoiden zielmolekülen durch kapillarplatten mit grosser innerer oberfläche
FR2813794B1 (fr) * 2000-09-08 2003-01-24 Pasteur Institut Procede de couplage, en solution, entre un peptide et un vecteur lipophile et ses applications
WO2004005342A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
EP1546200A2 (en) 2002-10-02 2005-06-29 Zealand Pharma A/S Stabilized exendin-4 compounds
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US20050176079A1 (en) 2004-02-09 2005-08-11 Chu Yong L. Polypeptide bioconjugates, methods of making the bioconjugates and assays employing the bioconjugates
US20080019911A1 (en) 2005-04-20 2008-01-24 Aimin Xu Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
EP1883652A2 (en) 2005-05-26 2008-02-06 Bristol-Myers Squibb Company N-terminally modified glp-1 receptor modulators
DK1891105T3 (da) 2005-06-13 2012-07-16 Imp Innovations Ltd Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
RU2429018C2 (ru) 2005-07-06 2011-09-20 Сейкагаку Корпорейшн Гель, полученный из фотосшитой гиалуроновой кислоты с введенным лекарственным средством
CN101357938B (zh) 2007-07-31 2013-07-03 周逸明 固相多肽合成Exenatide的制备方法
RU2010136023A (ru) 2008-02-01 2012-03-10 Асцендис Фарма Ас (Dk) Пролекарство, содержащее саморасщепляемый линкер
BRPI0915282A2 (pt) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
BRPI1008039A2 (pt) 2009-02-20 2016-10-04 Ipsen Pharma Sas composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
AU2010260058B2 (en) 2009-06-16 2015-09-24 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2654773B1 (en) 2010-12-22 2018-10-03 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR20130113493A (ko) 2011-01-03 2013-10-15 에프. 호프만-라 로슈 아게 항―ｄｉｇ 항체 및 펩티드에 접합되어 있는 디그옥시게닌의 복합체의 약학적 조성물
US20130289241A1 (en) 2012-04-26 2013-10-31 Shanghai Ambiopharm, Inc. Method for preparing exenatide
PT2864350T (pt) 2012-06-21 2018-05-14 Hoffmann La Roche Análogos do glucagon que apresentam uma atividade sobre o recetor do gip
ES2602486T3 (es) 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
CN103163233B (zh) 2012-07-12 2014-06-25 海南合瑞制药股份有限公司 固相合成胸腺肽α1的28肽阶段的缺失肽及检测方法
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
RU2662973C2 (ru) 2012-11-06 2018-07-31 Лез Опито Юниверситер Де Женев Пептидомиметики
SG11201503576XA (en) 2012-12-21 2015-06-29 Sanofi Sa Exendin-4 Derivatives
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080151A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
CN103819553A (zh) * 2013-12-27 2014-05-28 苏贤斌 一种使用固相和液相组合技术制备利西拉来的方法
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
CN104211801A (zh) * 2014-07-25 2014-12-17 杭州诺泰制药技术有限公司 一种制备利西拉来的方法
WO2016029324A1 (en) * 2014-08-29 2016-03-03 Rsem, Limited Partnership Azasulfurylpeptide-based cd36 modulators and uses thereof
CN104844706B (zh) 2015-06-10 2018-08-03 成都圣诺生物科技股份有限公司 一种合成利西拉来的方法
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
CA3003465A1 (en) * 2015-10-28 2017-05-04 Krishna Kumar Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
EP3433267B1 (en) * 2016-03-23 2022-08-24 Bachem Holding AG Method for preparing glucagon-like peptides
WO2017189925A1 (en) 2016-04-28 2017-11-02 C S Bio Co. Methods of preparing peptides
TW201821434A (zh) 2016-10-10 2018-06-16 法商賽諾菲公司 製備包含親脂性修飾的離胺酸側鏈的肽的方法
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
US11560402B2 (en) * 2018-04-10 2023-01-24 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
WO2019197469A1 (en) 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Lixisenatide synthesis with capping

Also Published As

Publication number Publication date
AU2019250362A1 (en) 2020-11-26
DK3774838T3 (da) 2022-10-31
JP7332620B2 (ja) 2023-08-23
US11028123B2 (en) 2021-06-08
SG11202010016QA (en) 2020-11-27
EP3774838B1 (en) 2022-08-10
JP2021521144A (ja) 2021-08-26
CN112218876A (zh) 2021-01-12
IL277836A (en) 2020-11-30
HUE059777T2 (hu) 2022-12-28
ES2928207T3 (es) 2022-11-16
US20190330263A1 (en) 2019-10-31
BR112020020647A2 (pt) 2021-02-23
CN112218876B (zh) 2024-10-15
EP3774838A1 (en) 2021-02-17
CA3096495A1 (en) 2019-10-17
WO2019197469A1 (en) 2019-10-17
KR20200142032A (ko) 2020-12-21

Similar Documents

Publication Publication Date Title
MX2021005254A (es) Produccion recombinante de una preparacion de peptido de colageno y uso de la misma.
MX2017016105A (es) Polinucleotidos y polipeptidos de adenovirus.
NZ605450A (en) Anti-siglec-15 antibody
NZ590860A (en) Fgf-r4 receptor-specific antagonists
EP3552622A3 (en) Priming of an immune response
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
PE20121033A1 (es) Produccion recombinante de peptidos
MX2017005268A (es) Tripeptidil peptidasas tolerantes a prolina y usos de las mismas.
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).
MX2019000082A (es) Una novedosa tagatosa-6-fosfato fosfatasa termoestable y un procedimiento para producir tagatosa usando la misma.
NZ753324A (en) Bivalent antibodies masked by coiled coils
MX2017005642A (es) Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
ZA202302340B (en) Compositions and methods for treating celiac sprue disease
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
MX2019002178A (es) Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
NZ730519A (en) Peptide microarrays and novel biomarkers for celiac disease
PH12016500403A1 (en) An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
WO2015107363A3 (en) Mycobacterial antigen composition
MX2021001129A (es) Metodo de purificacion de antigenos.
MX2019008056A (es) Agonistas del receptor pac1 (maxcaps) y usos de estos.
MX2020010715A (es) Sintesis de lixisenatida con taponamiento.
MX2019004116A (es) Metodo de preparacion de peptidos que comprenden una cadena lateral de lisina modificada lipofilicamente.
PH12021551055A1 (en) Klk5 inhibitory peptide
SG10201805039UA (en) Protease resistant peptides